Prospective Randomized Trial of Trimethoprim/Sulfamethoxazole versus Pyrimethamine and Sulfadiazine in the Treatment of Ocular Toxoplasmosis

Repurposing the Open Access Malaria Box To Discover Potent Inhibitors of Toxoplasma gondii and Entamoeba histolytica

“…The most effective available therapeutic combination is pyrimethamine plus sulfadiazine or the trisulfapyrimidines (e.g., a combination of sulfamerazine, sulfamethazine, and sulfapyrazine). These agents are active against tachyzoites and are synergistic when used in combination (43)(44)(45). These compounds belong to the pyrimidine scaffold.…”

Incidence and clinical characteristics in a Colombian cohort of ocular toxoplasmosis

“…10,11 The frequency of 17% of a positive IgM assay was lower than that reported previously of 47% for patients during the acute phase of ocular toxoplasmosis in the same region in Colombia by the high-sensitive assay ISAGA and of 37% in Iran. 12,13 This could be partly explained by the different commercial assays used. Our series includes a high number of congenital cases and we confirm that in these cases bilateral involvement was more frequent as reported by other authors.…”

“…Some differences between South American and European clinical case series have been found in the rate of congenital transmission, in the probability of symptoms in congenital infection, and in the difference in frequency of serological markers in ocular Incidence and clinical characteristics of ocular toxoplasmosis A de-la-Torre et al toxoplasmosis. 6,7,12 Therefore, it would be important to make a multicentre clinical study to confirm the existence of a more severe clinical picture in South America.…”

A typical chorioretinitis by toxoplasma

“…Nevertheless, and in accordance with other authors, no clear relationship was established [19]. Moreover, there is no apparent difference between treatment with cotrimoxazole and a combination of pyrimethamine with sulfadiazine [22,23]. However, it is important to incorporate corticosteroids into the treatment at 48 hours of the initiation of antiprotozoal therapy in order to avoid tissue destruction due to the inflammatory process.…”